Vaxcyte, Inc.
PCVX
주식 순위
#2081
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
주가
$64.29
시가총액
$9.86B
변동 (1일)
1.05%
변동 (1년)
51.66%
국가
US
거래 Vaxcyte, Inc. (PCVX)
카테고리
Healthcare
Vaxcyte, Inc. (PCVX)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 3.54
Vaxcyte, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 3.54입니다. 2023년 말 기준 P/B 비율은 4.92였습니다.
Vaxcyte, Inc.의 P/B 비율 기록 (2017 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 3.54 | 17.19% |
| 2024 | 3.02 | -38.58% |
| 2023 | 4.92 | 50.78% |
| 2022 | 3.26 | -24.99% |
| 2021 | 4.35 | 91.61% |
| 2020 | 2.27 | -343.31% |
| 2019 | -0.93 | -43.25% |
| 2018 | -1.64 | -154.55% |
| 2017 | 3.01 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | 76.63% |
US
|
|
| 13.2547 | 274.52% |
US
|
|
| 4.208 | 18.90% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 74.69% |
NL
|
